Clinical Trial: An Immunotherapy-Chemotherapy Regimen Combined with Anlotinib for Advanced Non-Small Cell Lung Cancer Guided by a Multimodal AI Model (TPS-Radscore): A Prospective, Multicenter Study (China)

Posted On: 2026-08-19

China, Aug. 19 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'An Immunotherapy-Chemotherapy Regimen Combined with Anlotinib for Advanced Non-Small Cell Lung Cancer Guided by a Multimodal AI Model (TPS-Radscore): A Prospective, Multicenter Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130346

Registration Time: 2026/08/18

Type: Interventional study

Primary Sponsor: Foshan Nanhai District People's Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338105

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: An Immunotherapy-Chemotherapy Regimen Combined with Anlotinib for Advanced Non-Small Cell Lung Cancer Guided by a Multimodal AI Model (TPS-Radscore): A Prospective, Multicenter Study (China)